Scinai Immunotherapeutics Ltd. (SCNI)
NASDAQ: SCNI · Real-Time Price · USD
0.9015
+0.0215 (2.44%)
At close: Oct 15, 2026, 4:00 PM EDT
0.8746
-0.0269 (-2.98%)
After-hours: Oct 15, 2026, 7:57 PM EDT
Scinai Immunotherapeutics Revenue
Scinai Immunotherapeutics had revenue of $460.00K in the quarter ending June 30, 2026, with 145.99% growth. This brings the company's revenue in the last twelve months to $1.49M, up 29.64% year-over-year. In the year 2025, Scinai Immunotherapeutics had annual revenue of $1.31M with 99.24% growth.
Revenue (ttm)
$1.49M
Revenue Growth
+29.64%
P/S Ratio
0.35
Revenue / Employee
$33,044
Employees
45
Market Cap
513.88K
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.31M | 653.00K | 99.24% |
| Dec 31, 2024 | 658.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Curis | 4.31M |
| Decoy Therapeutics | 227.63K |
| Biodexa Pharmaceuticals | 104.90K |
| Endovia Health Sciences | 32.09K |
| Virax Biolabs Group | 12.42K |
| Valion Bio | -86.00K |
SCNI News
- 1 day ago - Scinai Immunotherapeutics announces $4M private placement - TheFly
- 1 day ago - Scinai Immunotherapeutics Announces $4.0 Million Financing Through a Private Placement and Warrant Inducement - PRNewsWire
- 2 days ago - Scinai signs $5.1M development and clinical manufacturing agreement - TheFly
- 2 days ago - Scinai Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing Agreement - PRNewsWire
- 24 days ago - Scinai Immunotherapeutics regains Nasdaq compliance - TheFly
- 24 days ago - Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement - PRNewsWire
- 5 weeks ago - Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business - PRNewsWire
- 7 weeks ago - Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum - PRNewsWire